Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-04
DOI
10.3389/fmolb.2020.581828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis
- (2020) Takayuki Takeda et al. Journal of Clinical Medicine
- Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis
- (2019) Paolo Cameli et al. INFLAMMATION
- Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
- (2019) Steven D. Nathan et al. RESPIRATORY MEDICINE
- Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
- (2019) Jin Woo Song et al. RESPIROLOGY
- Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis
- (2019) Paolo Cameli et al. NITRIC OXIDE-BIOLOGY AND CHEMISTRY
- Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment
- (2019) Stefania Cerri et al. RESPIRATORY MEDICINE
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
- (2018) Bruno Crestani et al. Lancet Respiratory Medicine
- Pirfenidone improves survival in IPF: results from a real-life study
- (2018) George A. Margaritopoulos et al. BMC Pulmonary Medicine
- Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
- (2018) E. Bargagli et al. Pulmonology
- 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung
- (2017) Brian L. Graham et al. EUROPEAN RESPIRATORY JOURNAL
- An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)
- (2017) Ulrich Costabel et al. RESPIRATION
- Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
- (2017) Luca Richeldi et al. THORAX
- Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
- (2017) José Antonio Rodríguez-Portal Drugs in research & development
- Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis
- (2016) Masashi Bando et al. INTERNAL MEDICINE
- First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
- (2016) Wim A. Wuyts et al. LUNG
- Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
- (2016) Paola Rogliani et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor
- (2015) Martin Reck Expert Review of Anticancer Therapy
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenesis of Idiopathic Pulmonary Fibrosis
- (2013) Paul J. Wolters et al. Annual Review of Pathology-Mechanisms of Disease
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now